<SEC-DOCUMENT>0001171843-20-006632.txt : 20200924
<SEC-HEADER>0001171843-20-006632.hdr.sgml : 20200924
<ACCEPTANCE-DATETIME>20200924161507
ACCESSION NUMBER:		0001171843-20-006632
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20200924
FILED AS OF DATE:		20200924
DATE AS OF CHANGE:		20200924

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Genfit S.A.
		CENTRAL INDEX KEY:			0001757064
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38844
		FILM NUMBER:		201195437

	BUSINESS ADDRESS:	
		STREET 1:		PARC EURASANTE
		STREET 2:		885, AVENUE EUGENE AVINEE
		CITY:			LOOS
		STATE:			I0
		ZIP:			59120
		BUSINESS PHONE:		33 3 20 16 4000

	MAIL ADDRESS:	
		STREET 1:		PARC EURASANTE
		STREET 2:		885, AVENUE EUGENE AVINEE
		CITY:			LOOS
		STATE:			I0
		ZIP:			59120
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>f6k_092420.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<html>
<head>
     <title></title>
</head>
<body style="font: 10pt Times New Roman, Times, Serif">

<p style="font-size: 18pt; text-align: center; margin: 0pt 0"><b>UNITED STATES</b></p>

<p style="font-size: 18pt; text-align: center; margin: 0pt 0"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>Washington, D.C. 20549 </b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 18pt; text-align: center; margin: 0pt 0"><b>FORM 6-K </b></p>

<p style="font-size: 18pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>REPORT OF FOREIGN PRIVATE ISSUER</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>PURSUANT TO RULE 13a-16 OR 15d-16 </b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>Date of report: September 24, 2020 </b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>Commission File Number: 001-38844 </b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 24pt; text-align: center; margin: 0pt 0"><b>GENFIT S.A.</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>(Translation of registrant&rsquo;s name into English) </b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>Parc Eurasant&eacute;</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>885, avenue Eug&egrave;ne Avin&eacute;e</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>59120 Loos, France</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>(Address of principal executive office) </b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">Indicate by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F:</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">&#9746; Form 20-F &#9744; Form 40-F</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(1): &#9744;</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(7): &#9744;</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt; text-align: center"><b>EXHIBIT LIST </b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 6%">&nbsp;</td>
    <td style="vertical-align: bottom; width: 4%">&nbsp;</td>
    <td style="width: 90%">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td>
        <p style="font-size: 10pt; text-align: center; margin: 0pt 0; border-bottom: black 1pt solid"><b>Exhibit</b></p></td>
    <td>&nbsp;</td>
    <td>
        <p style="font-size: 10pt; text-align: center; margin: 0pt 0; border-bottom: black 1pt solid"><b>Description</b></p></td></tr>
<tr>
    <td>&nbsp;</td>
    <td colspan="2">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top"><a href="exh_991.htm"><font style="font-size: 10pt">99.1</font></a></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><a href="exh_991.htm"><font style="font-size: 10pt">Press Release dated September 24, 2020.</font></a></td></tr>
<tr>
    <td>&nbsp;</td>
    <td colspan="2">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td colspan="2">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
</table>
<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt; text-align: center"><b>SIGNATURES </b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 48%">&nbsp;</td>
    <td style="vertical-align: bottom; width: 1%">&nbsp;</td>
    <td style="width: 3%">&nbsp;</td>
    <td style="vertical-align: bottom; width: 1%">&nbsp;</td>
    <td style="width: 3%">&nbsp;</td>
    <td style="vertical-align: bottom; width: 1%">&nbsp;</td>
    <td style="width: 43%">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td colspan="3" style="vertical-align: top"><font style="font-size: 10pt"><b>GENFIT S.A.</b></font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td colspan="2">&nbsp;</td>
    <td colspan="2">&nbsp;</td>
    <td colspan="2">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top"><font style="font-size: 10pt">Date: September 24, 2020</font></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">By:</font></td>
    <td style="vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</td>
    <td style="vertical-align: top; border-bottom: black 1pt solid"><font style="font-size: 10pt">/s/ Pascal PRIGENT</font></td></tr>
<tr>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">Name: Pascal PRIGENT</font></td></tr>
<tr>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">Title: Chief Executive Officer</font></td></tr>
</table>

<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>

<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>

<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>

<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>

<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>

<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>

<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>

<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>

<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>

<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exh_991.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="hdr.jpg" ALT="" STYLE="height: 211px; width: 850px">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; color: rgb(0,84,120)"><B>GENFIT Announces First Patient
First Visit for ELATIVE Phase 3 Study Evaluating Elafibranor in PBC</B></P>

<P STYLE="font-size: 10pt; text-indent: -125.45pt; margin-top: 0pt; margin-bottom: 0pt; color: #005478">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="color: #005278"><B>Lille, France; Cambridge,
M.A.; September 24, 2020</B></FONT> - <B>GENFIT (Nasdaq and Euronext: GNFT)</B>, a late-stage biopharmaceutical company dedicated
to improving the lives of patients with metabolic and liver diseases<B>,</B> today announced the first patient first visit for
ELATIVE, the global, pivotal, Phase 3 study evaluating elafibranor in Primary Biliary Cholangitis (PBC).</P>

<P STYLE="font-size: 10pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">ELATIVE is a randomized, double blind,
placebo-controlled, global multicenter Phase 3 study evaluating the efficacy and safety of elafibranor, a dual PPAR alpha and
delta agonist, in PBC. The primary endpoint will evaluate the response to treatment defined by alkaline phosphatase (ALP)
&lt; 1.67 x upper limit of normal (ULN), total bilirubin (TB) &le; ULN and ALP decrease &ge; 15%. Key secondary endpoints
will include the effect of elafibranor on normalization of ALP and change in pruritus from baseline. The randomized study
(2:1, elafibranor:placebo) will evaluate approximately 150 patients with inadequate response to ursodeoxycholic acid (UDCA)
following 52 weeks of treatment.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">PBC is a severe cholestatic liver disease that impacts
and gradually destroys the bile ducts, leading to inflammation and scarring in the liver. This condition, if left untreated, can
lead to cirrhosis, liver failure and may ultimately require liver transplantation. There is no existing cure for PBC, and current
therapies are only able to potentially slow the progression of the disease. Approximately half<FONT STYLE="font-size: 10pt">1</FONT>
of patients with PBC are unable to benefit from existing therapies due to lack of response or intolerable side effects.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="color: #005278"><B>Kris V. Kowdley,
MD, Director at Liver Institute Northwest, Seattle, WA, and Clinical Professor at the Elson S. Floyd College of Medicine, Washington
State University,</B></FONT> commented: </P>

<P STYLE="font-size: 10pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&ldquo;<I>A significant percentage of patients
with PBC are in need of additional therapies and face a reduced quality of life due to the debilitating disease symptoms and treatment
side effects, including pruritus. This leaves healthcare professionals with limited therapeutic options and ongoing need for new
therapies, given that in the absence of treatment the median survival for some patients presenting with symptoms may be as short
as seven to eight years.2 The development of a new promising therapy with the potential to address both cholestasis and pruritus
provides hope for patients and healthcare providers in treating the PBC population.&rdquo;</I></P>

<P STYLE="font-size: 10pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">______________________</P>

<P STYLE="text-align: justify; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">1 Shah RA, Kowdley KV. Current and potential treatments for primary
biliary cholangitis. Lancet Gastroenterol Hepatol. 2020 Mar;5(3):306-315. doi: 10.1016/S2468-1253(19)30343-7. Epub 2019 Dec 2.
PMID: 31806572.</P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">2 Lindor et al. Hepatology 2019.</P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 93%"><P><B>GENFIT
                                         </B>| 885 Avenue Eug&egrave;ne Avin&eacute;e, 59120 Loos - FRANCE | +333 2016 4000 |
                                         www.genfit.com</P></TD><TD STYLE="width: 7%; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="hdr.jpg" ALT="" STYLE="height: 211px; width: 850px">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">In 2018, GENFIT announced positive Phase 2 data in
PBC, where elafibranor showed a clinically relevant improvement on the primary and composite biochemical endpoints providing early
confirmation of efficacy, a positive trend on pruritus improvement, while maintaining a favorable tolerability profile. Based upon
these data, elafibranor was granted Breakthrough Therapy designation by the Food and Drug Administration (FDA), as well as Orphan
Drug designation by the FDA and the European Medicines Agency (EMA).</P>

<P STYLE="font-size: 10pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="color: #005278"><B>Pascal Prigent,
CEO at GENFIT</B></FONT>, added: <I>&ldquo;I am proud of the GENFIT team, who have worked hard to achieve the first patient first
visit for ELATIVE amidst the ongoing challenges presented by the COVID-19 global pandemic. This is a significant milestone and
it means that we are now a step closer to hopefully bringing patients and caregivers a promising option to treat this debilitating
disease and its symptoms. We see an important potential for elafibranor in PBC and will provide further information at the upcoming
Corporate Update on September 30.&rdquo;</I></P>

<P STYLE="font-size: 10pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: #005478"><B>ABOUT PBC</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: #005478">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Primary biliary cholangitis (PBC) is a chronic, autoimmune
disease in which bile ducts in the liver are gradually destroyed. The damage to bile ducts can inhibit the liver&rsquo;s ability
to rid the body of toxins, and can lead to scarring of liver tissue, known as cirrhosis. Elafibranor, currently in a phase 3 clinical
trial for PBC (ELATIVE), has shown promising results for the treatment of PBC in a Phase 2 clinical trial, and was granted Breakthrough
Therapy designation by the FDA and Orphan Drug designation by the FDA and EMA in this condition.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: #005478"><B>ABOUT GENFIT</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: #005478">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">GENFIT is a late-stage biopharmaceutical
company dedicated to improving the lives of patients with metabolic and liver diseases. GENFIT is a pioneer in the field of nuclear
receptor-based drug discovery, with a rich history and strong scientific heritage spanning more than two decades. GENFIT has initiated
a Phase 3 clinical trial of elafibranor in patients with PBC. As part of GENFIT&rsquo;s comprehensive approach to clinical management
of patients with liver disease, the Company is also developing NIS4&trade;, a new, non-invasive blood-based diagnostic technology
which, if approved, could enable easier identification of patients with at-risk NASH. With facilities in Lille and Paris, France,
and Cambridge, MA, USA, the Company has approximately 200 employees. GENFIT is a publicly traded company listed on the Nasdaq
Global Select Market and on compartment B of Euronext&rsquo;s regulated market in Paris (Nasdaq and Euronext: GNFT). www.genfit.com</P>

<P STYLE="font-size: 10pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; color: #005478"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 93%"><P><B>GENFIT
                                         </B>| 885 Avenue Eug&egrave;ne Avin&eacute;e, 59120 Loos - FRANCE | +333 2016 4000 |
                                         www.genfit.com</P></TD><TD STYLE="width: 7%; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; color: #005478"><IMG SRC="hdr.jpg" ALT="" STYLE="height: 211px; width: 850px">&nbsp;</P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; color: #005478">&nbsp;</P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; color: #005478"><B>FORWARD LOOKING STATEMENTS</B></P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; color: #005478">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">This press release contains certain forward-looking
statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995, with respect to GENFIT,
including statements regarding the potential of elafibranor in PBC. The use of certain words, including &ldquo;believe,&rdquo;
&ldquo;potential,&rdquo; &ldquo;expect&rdquo; and &ldquo;will&rdquo; and similar expressions, is intended to identify forward-looking
statements. Although the Company believes its expectations are based on the current expectations and reasonable assumptions of
the Company&rsquo;s management, these forward-looking statements are subject to numerous known and unknown risks and uncertainties,
which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking
statements. These risks and uncertainties include, among other things, the uncertainties inherent in research and development,
including related to safety, biomarkers, progression of, and results from, its ongoing and planned clinical trials, review and
approvals by regulatory authorities of its drug and diagnostic candidates and the Company&rsquo;s continued ability to raise capital
to fund its development, as well as those risks and uncertainties discussed or identified in the Company&rsquo;s public filings
with the French Autorit&eacute; des march&eacute;s financiers (&ldquo;AMF&rdquo;), including those listed in Section 2.1 &ldquo;Main
Risks and Uncertainties&rdquo; of the Company&rsquo;s 2019 Universal Registration Document filed with the AMF on May 27, 2020 under
n&deg; D.20-0503, which is available on GENFIT&rsquo;s website (www.genfit.com) and on the website of the AMF (www.amf-france.org)
and public filings and reports filed with the U.S. Securities and Exchange Commission (&ldquo;SEC&rdquo;), including the Company&rsquo;s
20-F dated May 27, 2020. In addition, even if the Company&rsquo;s results, performance, financial condition and liquidity, and
the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive
of results or developments in future periods. These forward-looking statements speak only as of the date of publication of this
document. Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking
information or statements, whether as a result of new information, future events or otherwise.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: #005478"><B>GENFIT CONTACT</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: #005478">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><B>GENFIT </B>| Investors</P>

<P STYLE="font-size: 10pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Naomi EICHENBAUM &ndash; Investor Relations | Tel: +1
(617) 714 5252 | investors@genfit.com</P>

<P STYLE="font-size: 10pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><B>PRESS RELATIONS </B>| Media</P>

<P STYLE="font-size: 10pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">H&eacute;l&egrave;ne LAVIN &ndash; Press
Relations | Tel: +3 33 2016 4000 | helene.lavin@genfit.com</P>

<P STYLE="font-size: 10pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; width: 50%; text-align: left"><FONT STYLE="font-size: 10pt"><B>GENFIT</B> | 885 Avenue Eug&egrave;ne
    Avin&eacute;e, 59120 Loos - FRANCE | +333 2016 4000 | www.genfit.com</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 49%; text-align: right"><FONT STYLE="font-size: 10pt">3</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>hdr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 hdr.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $F!*$# 2(  A$! Q$!_\0
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MUM2*&2J)C&X\5#*175,TDJ#;BK01:AFP :$)F-=P@DUSE_#AN*Z:Z8#-85X
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MPHHI":H0M)FFEJ;DTP),TN:BS3MU B2BH]U.#4 .I#1F@T#$I:!12 *2EHH
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M&[2.SC!\]^KD?UJ><M0.5$ND:7K*V\NF33*C<G'6O3V@L-9TJ-+:"&UC(''
M:O#K6_UWQG>BUTM/FSS+BI_$%OXE\$[$NM2+AOO8.2*3E<KE2/6O%WB5/#.@
M)9I;%XRNUG*\_A7D^DZUJ$VJLWAB.6:X8Y<<X%,TSXEW(06NJ0+>6K<$R#)
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M9">2E-2(<3SE2I; P<],T\+@9["O2--\/^%/%,+/IC.I_O8^[]:Y[Q)X*N=
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M'@$DX HL%Q*45']H@_Y[1_\ ?8I?M$'_ #VC_P"^A3L+F1)013/M$'_/:/\
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M#5JZ$+KEUGMOC##^=</M/[_X'IJC_P!.U]YTT^CIIOP\N],DG^UQPV4H21E
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M-6A3:<FM3YKW-ZFMSPIH\?B#Q%:Z;/-)%'+NR\>,C"D]_I6'76?#3_D>]/\
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M_A4DVO:=!M\VXV[D#CY&Z'H>E1_:$;7YE^!?]GO:S_$RK#PU>6'@VYT?[?\
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MG)N^SO\ CY^70Y?7!)%K5O,#<*@B(,D,>\@\UH:7?)/B BY:0 DR30[,\_\
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M+XI7.F0_]=Q_Z"U ',PK@"KL:U7B7@5:C&*YYG3!%E%XJ0)3$/%2BN=G4EH
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M*V!5BTU:6U&PKO7IC-0S:;=F1F*%\\X7K55(I8Y0LD3Q_P"\*!,Z2QGC4-<
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M9[;<QXJG);'TK>DAR34#6^>U2P,182O44,".E:C6W/2H9+;@\4FD,].T<_\
M$CT__KVC_P#015T-5/2%QHE@/2VC_P#015OI7.S=$JM4JFH%-3*: )13A3 :
M>* %Q12TAH *4"FT]10,<!3Q2 4X4@"G48I: $HI:*0Q**6B@0TBF$5(:::8
M$)%(!4A% % "!:?B@4Z@!N*,4ZB@!A%,85(::128T0D4Y:5A2"H90X4ZFTM
MPI:2EIB%[4TTN:0FFB6)24$TF:LD6DHS29H 6DHS29H&+2BD%.%2QH*<*0"G
M 5)0M%+BC% "44M% "4E*:2F(0TPTXTTTT)C#3*>::13$-K'\2#.G1_]=A_(
MULXK*\01[[",?]-1_(T,J"NT<NB<U85,GI3XK<\5;2#VK!K4]2$4D5Q$?2I%
MB-75B'I3Q%STJ' ?/8H%<=J@D%:CP^U0O /2I<!J9E,IS493GI6DT(':H6B
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MPCK!_P"9RU3_ +X2NL IX%2ZLOZ2&J,/Z;.2'A#6/^ASU7_OA*7_ (1#6?\
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M4I%<[W-T0[:4+4F*4"D!'MI,5-MII6@"$U+#3&%/BXH M+4HJ)34@H D%*&
M[TS/!KYG\.>'/^$I\4/I8N_LN_S'\SR]^,<XQD?SJZ=)33;=K&%:NZ;BDKMG
MTWN'8BEKYT\3>%M6^'UW;7-OJ3-'*3Y4\!,;!ACAES_4UZ]H>KS:[\-5U&YP
M)I;.42$#&67<I/X[<_C3G1Y4I)W3%3Q#E)QE&S1UA([FD)';FOFGP7X2_P"$
MOU.XLQ>_9/)A\W?Y7F9^8#&-P]:L:SI.M?#G78/(OR"X\R*:$D*X!P0R_P Q
MSUK3ZNN;E4M3)8R7+SN/N^I]'4W=5#1=1&K:'87X4*;F!)2HZ*2 2/P/%>!>
M-+;[;\3KZUW[/.NHX]V,[<A1G'XUG2I<\FF[6-JU?V<5)*]SZ++4A:O(C\$3
M_P!##_Y)?_;*[C2;!/!G@S[/).;I-/AEE:0)LWC+.>,G'7%*4(KX97'"I4;]
M^-EZG1EJ3-?/^FVVM_$WQ!.+K4/+C1?,8')2)<X 5,_Y[FNOTCP-XE\,ZU9R
M6&LFYT[SE%Q$&,>4SR=A)!X]#GTJY48QT<M3.&(E/6,7R]SU#=1NKC_B%XDN
M/#GAOS;,A;JXD$,;$9V<$EOR'ZUYSX<\":EXQL&UFZU@Q%W81M(IE=B#R2<C
M'/UHA23CS2=D54Q#C/V<(W9[KOHWUP_@S1/$6@7US:ZI?F\T_P L>0WF%@K9
MZ8/(X[=*['=6<HI.R=S6G)RC=JQ8W49J$-7SGI.A?\))XRETS[3]F\V64^9L
MWXQD],CT]:JG24TVW:QG7KNFXI*[9](DTPFOG[Q+X5U3P)<V]U;Z@7CD8B.>
M',;!AS@C/]3WKV#P=K4FO>%K*_GP9V4I+@8RRDC/XXS^-35H\L5.+NBJ&(YY
MN$HV:-^C->%?%CGQG_V[1_S-;$/P>\Z".7^WL;U#8^Q],C_?JO8045*4K7\B
M'BIRG*$(7MYGK^:45S/@[PU_PBFDRV'VS[5YDYFW^5LQE5&,9/\ =_6O*;__
M )+&G_87B_\ 0UHITE-M)[#JUW3C%RCJSWS-&:;FJ6KG_B37W_7O)_Z":S6Y
MNW97+^:45\W>#O#'_"6:O+8?;/LOEP&;?Y6_.&48QD?WOTKN8O@QY<J/_;^=
MK X^Q_\ V=;3I0@[2E^!RT\15J+FC#3U/6@:4&F"O,OB_J,DL.F:#; O-=2^
M:R+U/\*#\23^58PASR43IJU%2@YGJ5+7BGP=U4VFNWFD2DJMS'O13V=.H_(G
M_OFO:Z=6G[.7**C656'.@S1]*\-\8:]JWBGQLWAZRN6@MDN3:I&'*JS X9GQ
MUYS^'ZZ8^%.OZ.HN-$\0#[2HR44-#D]P""<_CBK]BDES2LV8_692D^2-TCV"
MDJKIPN5TJU%[_P ?0A03<C[^T;NG'7/2OFWPGX>_X2C7$TS[5]FW(S^9Y>_&
M!GID?SI4J*FFV[6*KXATW%*-VSZ<SBC=7D!^">/^9A_\DO\ [97JD*>3;QQ9
MSL0+G&,X%3.$%\,KFE*=25^>-OG<M;A32U1;J,UG8U),THI@-/%,0ZEI*6F(
M6DI:* &FLK7#BR0_]-!_(UJ$UC^(6(T]/^N@_D::W$W8PQ,,]:D\\!>M9$DK
M+SFH6O& ZTY*YK3K6-U+H ]:D^U@C[U<N=0QWI\=\&'WJQ9VPJ1:.C-S_M4Q
MKCC@UCI<AN]3"7(ZUE)E\R+WG>IJ6.0'IUK+WL35JWSD4HR,YLUHQTJZB\"J
M< R!5Z/G%=,3DF6(EJTJU#&.15I15,R$"T['K3P*6@1&5%0.M6R*C<<4 4]M
M%3[1104?)XBY%6(8\'ZU9-O@CBIHX.G%<O.=7*26T.<5J00]JBM(.G%:T,)'
M:H<C6*(UBXZ5/'!D]*F6+(YJ94P!4-W*L2VMF#VK6BM@JCBJMJ3BM1#\M:01
MSU=!FP 4HR< "G$C::1>9$ _&NR"T.![GG'Q4NPSV]L#R*\PC:22X**,]N*[
M3XES[_$;*#]T5Q]@6CCE88&3U'6G(T3'FUCC'EO+O;.6YZ5 [^9)Y5O 1"O5
M\5HWJVUOI2HB[IW.6D[U-9ZM]GLOLT,,4@Q\S,.:2V QIV2"W*H,L>M0%U,
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M'_']Y$?VCI_K-HW?=XZYZ<5>---$ZG-T2]!TZ7LW?F;]6)1BCO2BH-0 IP%
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M'.,8IX.%%60PVT$<4;J3=3$-*TS%/+4UC0 TKFFE:7<12%J!B;:7%-+4;J
MCVII/:E,E,+BBP,:4^;-68N"*K;N:G1A@4T2V:UM-C%:4=S@=:PHI,586;WK
M1,EHV_M1]:2.Z^?K6,9\=Z:ES\_6G<D]_P!&?.BV!];>/_T$5H UCZ"^[P_I
MI];6+_T 5JJ:Q9LMB84\5&M2"D M--+2&@"-A43#-3$4PB@" KS3E%/Q2A:
M$Q2&I,4TB@"(U8A/RU$14D5 $X-.%, IPI#'4AHHH 8XXJ(FIGZ5 :8AC&F<
MT\TJI0 S:32A#4X04\)2&0!<5(!4FRC;3$(*<*0"G"@ I<444AB44IH I@)B
MDVT\"G!:0B+;2;*GQ2$4#*Y6DP:G*TA6DT-$0IP%.VT8I6'<3%+124K#N.!I
M::*7-,!:2DS1F@0&FDTI-,-,EA3A3*<#5"'BEIN:7- "YI,T4E(8M%*!2XI
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M/CK6;K!3[443H!VJDF0>#TIDFG8P>3?JRCY%.<FEUR]6ZNP%_AJ2R?8H=SN
MYQ6BUIINIQ95A'+4C.=A1I74+SSR!6TMW':%%. .ZFFOI,NFQM,GSCU%948:
M\GR22V>*!G2WJVFK:?A 8IE'!]::=&'_  C\,JX\\-AS[5D6=T8+EX902_\
M#6\TDITHJ5+!NH7M0,NV(%U"=*A?]^P&,]ZU_&4=M#H6G62E#=P@"0CUK%\,
M13VETMQ<KM"J=C'K6;?W#7>MRDEPN=Q#=S4]0Z&O8+FWYY/%6?+!ZBF6/$/
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MJ.&..123U-1,[B+9+VJ&)COX- %@Q>4Y*U#+YC'+ XJVA 3+&CS8VX.* *"
MNP&*THXEMX"9%!STJ+8I<%2*6Z9I%"@]*"BGYK;VPQ"]A4L5RY&P=^N:A,<@
M/"Y%2VHRYW#%(1;8I%#VW&G0QVTJ8<[7[52N7R<$\"HQ($&><T :A\.SSCS+
M-Q(>I6JMRKVJ&*=6CE'8BI+2_FC(>"5HF'>MY=6@U&(07T"%O^>O>D!R)!X8
M\\9I]NDDS_)D 'FM#4-)$2EX)=R9X%6=/:*&S<R*-VVF!2BO&M9R%)7%:']J
M0W416=5/^UWK#E832-S448PVT9/M38&S:HL<S/$/D]:IWYFDE+[&(]:F$OV>
MVQG%6;75PBB.2)9%/4TAF&#D\@[JT(L00EAM)Q6V-%TO5$\ZVN!%-UV&L;4K
M.XL\*Z%AZKTI-B*L5U)%(Q5R,^E;-AK\UM@.%F4]G&:YTMQ@#&:O65J[*9 .
MG>F!T=U%8ZM$9(4$<N.@]:YFXLYK61O,7\13ENWMYB0QX/05;FU%;B'YP"QH
M CT>S6Z8LXR!FJMRWDW+$'D' K7L(FBA8I\K-T%9=]:W5O*TDT#%3SG'%%QB
MQ:A*$PQ)!K4L5.?,WJN[N:PK=#))D<#TJY=3;8A&IQB@#3N_#4\\1N+642D\
M^6#\U9"6<L4P6X0Q,O4,*L6&K7%I*&CE((]ZW9=035(-MRJ;R.&'6@1SUS,<
M&-"% ]*BMI'SM3.?6I+VQ>WDWJ25]34FE1 SL_4>E &I97S?ZB1]V1]TU%:6
MZQZHS@ +[5D3N_V]C$>AZ"M?3V$$>^;DM2 CE2-;]IP0<=*T](OB]U@G"C[P
M/>J-_8!'BN(6)1SR*>\/D7JOD*I7CVH&=']H:]UJW@4$+N!&.E4-6E6Z\13D
M*%"#9A>E: NU70C)LVS1_=<#FL"S9ICYK??=LDT=1]#?M7"VR^HJ;S0<^E5U
MB8  =,4FQN>:TL9EGS!3?,%0;']::4:D(G,@HWC%5]K4A#8H&B<N*3>*KX:F
MD-3&6MPI"U5<L*0EZ0%DL*3(JL6:@,:!%@M3#408YI<DT /X-(1[TE% "%<C
MK3,#<!3FSFB-<N,T ?1OA=?^*:TK_KSA_P#0!6\M87ADX\-Z7_UZ1?\ H K<
M3I4E$BT\"F+4@I **7% I:!C2*:13Z::!$3"HFZU.U0/3$)FC-,S2YI@!I%/
MS4AI!]X4 6QTI0::#P*,U(Q^:,T@-&:8 :K/PU3DU!)UH %-2J:K@U*C4 34
MHI!S2BD M+24A-, ---&:3K3$%.44@%2 4 *!3Q2 4X4ABBG4@I10 44M%(!
M*,444 &*3%+10,3%(13J,4"(\48I^*3%,!N*,4[%+B@!N*,4[%&* &XI"*?B
MFF@!A%1L*F-1L* (#29YI["HCUI,:)%-/%1+4JUF6.%4M4'^C+_OC^1J[534
M_P#CW7_?'\C4S^%EP^)&&_%0[N:L256(YKE.LMPMFKT7(%9T-:4 Z5O YJA*
M%I=M2 9IQ3C-:F2("GRDU4G3(Z5HE.*ADBR*EHI'-WD1 .!6*ZLK&NPGMMX/
M%8]Q8G<>*YYQ.F$]#*CD*UI6USG S4+61 Z4^&U8$<5*BRI23-FWDW 5I1+\
MM9MI&5 S6K"M=$#FJ,E44[%/"XIVWBMC%D6VBI-M%,#RW_A5^M?\_6G_ /?Q
M_P#XBIH/AIK,39^TV/X2/_\ $445C&"-?:R[FO;^"=4B'S7%H?H[?_$UHQ>%
M[].LUO\ @S?X445I9$.39970+L=9(/S/^%2#0KH?\M(?^^C_ (444[(+L=_8
M=U_STA_,_P"%1MH%T?\ EI#_ -]'_"BB@5V1GP]>'_EK!^9_PI#X:OB1^]M_
M^^F_PHHHL*[*.N^#K[5-#GLQ):[V'RL[-@?^.UY1)\ /%3 [=0T89/\ SVE_
M^-T450A\'P"\41C#WVBGZ32__&Z5O@)XJ/W=0T8?]MI?_C=%%,D%^ OBS&7U
M'1R?^NTO_P ;I)O@'XI< )?Z,!WS-+_\;HHH KI^SYXJCE^74=&V'MYTO_QN
MI(?@'XMBF;_B8Z+L/;SI?_C=%%,!TG[/_BB1B3?Z-_W^E_\ C=1K^SYXI5LB
M_P!%_P"_TO\ \;HHI $G[/\ XK*X74-%'_;:7_XW4!_9V\7'_F(Z)_W_ )?_
M (U111<99C_9_P#%*)C^T-&S_P!=I?\ XW3!^S_XM$N?[1T7_O\ 2_\ QNBB
M@983X">*D/\ Q_Z*1_UVE_\ C=/_ .% :]*29+_2T/;RY9/_ (W112 HR_L]
M>*C(?+U'1MG;=-+G_P!%TW_AGCQ=N!_M'1,?]=Y?_C5%%,"T?@!XG\@H+[1M
MWKYTO_QNJR_L^>+E;/\ :6B_]_I?_C=%% $R? /Q>J<ZGHQ'IY\O_P ;J<_
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D_OH_X58CMF'=:**=D2Y-DWE'U%'EMZBBBJ)#RV]11115 ?_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
